Inogen, Inc. (INGN) SEC Filings & Earnings Calls
EquiReason read 15 Inogen, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-30 — Inogen divests U.S. oxygen rental business to Rotech for ~$25M, signs supply agreement, increases buyback authorization by $15M; expects higher revenue growth and adjusted operatin.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 188.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
30 Sep 20268-K · 1.01, 7.01, 8.01Inogen divests U.S. oxygen rental business to Rotech for ~$25M, signs supply agreement, increases buyback authorization by $15M; expects higher revenue growth and adjusted operating income.being acquiredopen
Figures in the filing · each found in the filing text
| Rental Business Revenue · Rental Business · H1-2026 | $24M | -10% y/y |
Guidance
Expects higher revenue growth and adjusted operating income post-divestiture; no quantified guidance provided.
Risks flagged
Transaction closing conditions and patient transition risks.
“Transaction subject to customary closing conditions; patient transition and continued servicing of rental patients.”
Accounting treatment and final proceeds may differ from estimates.
“Subject to post-closing reconciliation; expected classification as discontinued operations subject to final accounting analysis.”
7 Aug 202610-QInogen reported Q2 2026 revenue of $95.1M, up 3% YoY, with improved gross margins but continued net loss.earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q2-2026 | $95M | +3% y/y |
| Portable units sold · Q2-2026 | 53,300 | +12% y/y |
| Gross margin percentage - sales revenue · Sales · Q2-2026 | 46.2% | |
| Gross margin percentage - rental revenue · Rental · Q2-2026 | 40.6% | |
| Cash and cash equivalents · 2026-06-30 | $87M |
Risks flagged
Rental revenue decline
“Rental revenue decreased $1.5 million, or 11.8%, for the three months ended June 30, 2026 from the three months ended June 30, 2025. The decrease in rental revenue was primarily related to fewer patients on service.” · word for word
U.S. sales decline
“U.S. sales decreased 2.3% for the three months ended June 30, 2026 compared to the three months ended June 30, 2025, primarily due to channel mix versus the comparable period in 2025.” · word for word
6 Aug 20268-K · 2.02Revenue $95M (+3% y/y); International revenue $41M (+15% y/y); GAAP net loss $-4M; Guidance: FY2026 adjusted EBITDA ~$4.0M (from $2.7M in 2025); revenue $355-361Mearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $95M | +3% y/y |
| International revenue · International · Q2-2026 | $41M | +15% y/y |
| GAAP net loss · Q2-2026 | $-4M | |
| Adjusted EBITDA · Q2-2026 | $2M | +15% y/y |
| Cash, cash equivalents, marketable securities, and restricted cash · Q2-2026 | $107M | |
| Gross margin · Q2-2026 | 45.5% | |
| Adjusted gross margin · Q2-2026 | 45.6% | |
| Operating cash flow · Q2-2026 | $3M | |
| Share repurchases · H1-2026 | $8M |
Guidance
FY2026 adjusted EBITDA ~$4.0M (from $2.7M in 2025); revenue $355-361M
Raised adjusted EBITDA guidance significantly; revenue guidance implies ~3% growth.
Risks flagged
U.S. sales and rentals still below prior year; channel mix shift.
“U.S. sales and rentals remained below the prior-year period.” · word for word
1 Jul 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)open
Risks flagged
Potential disruption during leadership transition.
“New COO appointment may cause short-term operational adjustments.”
11 Jun 20268-K · 5.02, 5.07Reported the departure of a director or principal officer (CEO/CFO change); submitted matters to a vote of security holdersopen
Risks flagged
Shareholder dilution from increased equity awards.
“Approval of additional 750,000 shares for equity incentive plan.”
8 May 202610-QTotal revenue $85M (+3% y/y); Sales revenue $72M (+6% y/y); Rental revenue $13M (-8% y/y)open
Figures in the filing · each found in the filing text
| Total revenue · Q1-2026 | $85M | +3% y/y |
| Sales revenue · Sales · Q1-2026 | $72M | +6% y/y |
| Rental revenue · Rental · Q1-2026 | $13M | -8% y/y |
| Gross margin percentage · Q1-2026 | 44.5% | |
| Net loss · Q1-2026 | $-8M | -35% y/y |
| Cash and cash equivalents · 2026-03-31 | $93M | |
| Oxygen systems sold · Q1-2026 | 49,000 | +14% y/y |
| U.S. sales revenue · U.S. · Q1-2026 | $35M | -5% y/y |
| International sales revenue · International · Q1-2026 | $38M | +18% y/y |
| Operating cash flow · Q1-2026 | $-7M | +60% y/y |
Risks flagged
U.S. sales decline and rental revenue erosion
“U.S. sales decreased 4.8% and rental revenue decreased 8.0% YoY.”
Widening net loss
“Net loss increased 34.8% YoY to $8.3 million.”
7 May 20268-K · 2.02Revenue grew 3.4% to $85.1M; net loss widened to $8.3M; adjusted EBITDA negative $1.4M; full-year guidance reiterated; $30M buyback authorized.earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q1-2026 | $85M | +3% y/y |
| Sales revenue · Q1-2026 | $72M | |
| Rental revenue · Q1-2026 | $13M | |
| Gross margin · Q1-2026 | 44.5% | |
| Adjusted gross margin · Q1-2026 | 44.7% | |
| Net loss · Q1-2026 | $-8M | +35% y/y |
| Adjusted net loss · Q1-2026 | $-4M | +38% y/y |
| Adjusted EBITDA · Q1-2026 | $-1M | -3600% y/y |
| Cash, cash equivalents, marketable securities, and restricted cash · Q1-2026 | $112M | |
| Shares repurchased · Q1-2026 | 298,100 |
Guidance
Q2 2026 revenue $94M-$97M; FY2026 revenue $366M-$373M
Full-year 2026 revenue guidance reiterated at $366M-$373M; Q2 2026 revenue guided $94M-$97M; company committed to positive adjusted EBITDA improvement
Risks flagged
Net loss widened despite revenue growth
“GAAP net loss for the first quarter of 2026 was $8.3 million compared to a net loss of $6.2 million in the prior-year period” · word for word
Adjusted EBITDA turned negative
“Adjusted EBITDA was negative $1.4 million in the first quarter of 2026, compared to positive $0.04 million in the prior-year period” · word for word
28 Apr 2026DEF 14AProxy filing for 2026 Annual Meeting; includes cooperation agreement with activist, board declassification proposal, and equity plan amendment.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $349M | +4% y/y |
| Gross Margin · FY2025 | 44.2% | |
| Net Loss · FY2025 | $-23M | -37% y/y |
| Adjusted EBITDA · FY2025 | $3M | +128% y/y |
Risks flagged
Below-target performance on key metrics
“Revenue of $348.7 million (resulting in a percentage achievement of 0%) and Adjusted EBITDA of positive $3.7 million (resulting in a percentage achievement of 120%).” · word for word
High equity dilution from equity plan
“overhang level from 12.0%...to 14.0%”
6 Apr 20268-K · 1.01, 5.02, 7.01Inogen entered a Cooperation Agreement with Kent Lake Partners LP, an activist investor, appointing a board member and agreeing to standstill and voting provisions, resolving activist pressure.open
Risks flagged
Activist involvement may lead to strategic shifts or pressure on management.
“Standstill provisions and board appointment suggest activist influence.”
30 Mar 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)open
Risks flagged
Transition risk as former CFO steps down; new CFO compensation includes performance-based equity
“Michael Bourque steps down as CFO; Richardson's PSUs tied to performance goals”
27 Feb 202610-KNet loss $-23M (-37% y/y); Adjusted EBITDA $3M; Cash and cash equivalents $104Mopen
Figures in the filing · each found in the filing text
| Net loss · FY2025 | $-23M | -37% y/y |
| Adjusted EBITDA · FY2025 | $3M | |
| Cash and cash equivalents · 2025-12-31 | $104M | |
| Capped patients as percentage of total · 2025-12-31 | 17.6% | |
| International revenue percentage · FY2025 | 39.8% | |
| Operating cash flow · FY2025 | $-11M |
Risks flagged
Medicare Reimbursement Risk
“We expect that the stationary oxygen and non-delivery ambulatory oxygen reimbursement rates will continue to fluctuate, and a large negative payment adjustment would adversely affect our business.” · word for word
Customer Concentration Risk
“One customer represented more than 10% of our net accounts receivable balance with a net account receivable balance of $3.3 million as of December 31, 2024.” · word for word
International Operations Risk
“Engaging in international business inherently involves a number of difficulties and risks, including export or import delays and restrictions.” · word for word
24 Feb 20268-K · 2.02, 7.01Total revenue $349M (+4% y/y); Total gross margin 44.2; Total operating loss $-30M (+29% y/y); Guidance: FY 2026 revenue $366M-$373M, ~6% growth at midpointearningsopen
Figures in the filing · each found in the filing text
| Total revenue · FY2025 | $349M | +4% y/y |
| Total gross margin · FY2025 | 44.2% | |
| Total operating loss · FY2025 | $-30M | +29% y/y |
| GAAP net loss · FY2025 | $-23M | +37% y/y |
| Adjusted EBITDA · FY2025 | $3M | +128% y/y |
| Cash, cash equivalents, marketable securities, and restricted cash · Q4-2025 | $121M |
Guidance
FY 2026 revenue $366M-$373M, ~6% growth at midpoint
FY 2026 revenue guidance implies ~6% growth; Q1 2026 revenue expected in line with Q1 2025; management confident in accelerating growth and profitability
Risks flagged
Channel mix pressure on gross margin
“Total gross margin of 44.2% in the full year 2025 decreased from 46.1% in the comparable period in 2024, primarily the result of changing channel mix” · word for word
12 Jan 20268-K · 2.02Total revenue $82M (+2% y/y); Total revenue FY $349M (+4% y/y)earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q4-2025 | $82M | +2% y/y |
| Total revenue FY · FY2025 | $349M | +4% y/y |
Risks flagged
Order timing shift: some large customer orders delayed to H1 2026.
“we experienced a shift in the timing of a few large customer orders into the first half of 2026” · word for word
6 Nov 202510-QInogen reported Q3 2025 revenue of $92.4M, up 4% YoY, with net loss improving to $5.3M from $6.0M; no explicit beat or miss stated.earningsopen
Figures in the filing · each found in the filing text
| Total Revenue · Q3-2025 | $92M | +4% y/y |
| Sales Revenue · Sales · Q3-2025 | $79M | +6% y/y |
| Rental Revenue · Rental · Q3-2025 | $13M | -4% y/y |
| Oxygen Systems Sold · Q3-2025 | 51,100 | +16% y/y |
| Total Gross Margin · Q3-2025 | 44.7% | |
| Net Loss · Q3-2025 | $-5M | +11% y/y |
| Cash and Cash Equivalents · 2025-09-30 | $107M |
Risks flagged
Reimbursement Rate Pressure
“Rental revenue decreased $0.6 million, or 4.4%, for the three months ended September 30, 2025 from the three months ended September 30, 2024. The decrease in rental revenue was primarily related to a higher mix of lower private-payor reimbursement rates.” · word for word
Direct-to-Consumer Sales Decline
“Domestic direct-to-consumer sales decreased 17.9% for the three months ended September 30, 2025 compared to the three months ended September 30, 2024, primarily driven by lower volume and average selling price.” · word for word
5 Nov 20258-K · 2.02Revenue $92M (+4% y/y); Gross Margin 44.7; Net Loss $-5M (+12% y/y); Guidance: Adjusted EBITDA guidance raised to ~$2M from prior; revenue guidance reiterated at $354M-$357Mearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $92M | +4% y/y |
| Gross Margin · Q3-2025 | 44.7% | |
| Net Loss · Q3-2025 | $-5M | +12% y/y |
| Adjusted EBITDA · Q3-2025 | $2M | +360% y/y |
| Cash and Equivalents · Q3-2025 | $125M | |
| Operating Cash Flow · Q3-2025 | $2M |
Guidance
Adjusted EBITDA guidance raised to ~$2M from prior; revenue guidance reiterated at $354M-$357M
Revenue guidance reiterated, adjusted EBITDA raised; Q4 revenue expected $87M-$90M.
Risks flagged
Gross margin pressure from B2B mix shift
“Gross margin declined to 44.7% from 46.5% due to increased B2B sales as a percentage of total revenue.”
Inogen, Inc. — questions
- What did Inogen, Inc. file recently?
- 15 SEC filings in the last 12 months. Latest: 8-K on 2026-09-30 — Inogen divests U.S. oxygen rental business to Rotech for ~$25M, signs supply agreement, increases buyback authorization by $15M; expects higher revenue growth and adjusted operating income.
Every figure on this page comes from Inogen, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.